早期声门癌经口激光显微手术患者获较高语音基频  

Transoral laser microsurgery elevates fundamental frequency in early glottic cancer

作　　者：Luo CM Fang T J Lin CY 何双八[2] 

机构地区：[1]不详 [2]安徽医科大学附属省立医院耳鼻咽喉头颈外科

出　　处：《中国医学文摘（耳鼻咽喉科学）》2014年第6期346-350,共5页Chinese Medical Digest(Otorhinolaryngology)

基　　金：长庚纪念医院资助(CMRPG270011)

摘　　要：目的评估早期声门癌患者治疗后嗓音特征和生活质量的长期疗效。研究设计回顾性分析台湾一家医学中心的患者资料。方法 42例声门癌患者接受放疗(radiation therapy,RT)或经口激光显微手术(transoral laser microsurgery,TLM)治疗12个月后评估其嗓音和生活质量。结果 24例患者接受RT,18例患者接受TLM。两组患者无听力学和空气动力学差异,对于男性患者仅有发音基频的差异。在癌症治疗——头颈调查的功能性评估中,TLM治疗组比RT治疗组能更好地交流,但无嗓音质量和强度的差异。同样,这两组在嗓音障碍指数10(VHI-10)评估中也没有显著性差异。结论接受TLM治疗的男性患者比接受RT治疗组的男性患者,具有较高的发音基频。对于早期声门癌患者,无论是接受TLM治疗,还是接受RT治疗,嗓音相关的生活质量是相似的;但是接受TLM治疗患者具有更好的交流能力。Objective To evaluate the long-term voice characteristics and quality of life of early glottic cancer patients after definitive treatment. Study Design Case series with chart review in a tertiary care medical center in Taiwan. Methods Forty-two consecutive patients who received radiation therapy （RT） or transoral laser microsurgery （TLM） for early glottic cancer over 12 months were evaluated for voice laboratory data and quality-of-life measurements. Results Twenty-four patients received RT, and 18 underwent TLM. There was no difference between the two groups on acoustic and aerodynamic voice measures except for modal fundamental frequency in males. In the Functional Assessment of Cancer Therapy-Head and Neck survey, the TLM group had better communication than the RT group, but there were no differences in voice quality and strength. There was also no significant difference in the Voice Handicap Index 10 evaluation. Conclusions Male patients who received TLM have higher modal fundamental frequency than male patients who received RT and norms. Voice-related life quality is similar in patients regardless of RT or TLM treatment for early glot-tic cancer, but those who receive TLM have better communication abilities than those who receive RT.

关 键 词：生活质量(Quality of life):声带癌(glottic cancer) 发音质量(voice outcome) 质量评估(outcome measurements) 

分 类 号：R739.65[医药卫生—肿瘤]